Study identifier:D9615C00021
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase I, Randomised, Open-label, Multi-National Study to Evaluate the Pharmacokinetics of Repeated Once-Daily Intravenous Doses of Esomeprazole in Paediatric Patients 0 to 17 years old, inclusive.
pharmacokinetics
Phase 1
No
esomeprazole
All
42
Interventional
N/A - 17 Years
Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The purpose of this research study is to evaluate how much of repeated once daily intravenous (IV, meaning through a vein) doses of esomeprazole gets into the bloodstream of hospitalized children aged 0-17 years old that require acid suppression therapy.
Location
Location
NORTH ADELAIDE, SA, Australia
Location
BRUSSELS (JETTE), BELGIUM, Belgium
Location
BUDAPEST, Hungary
Location
GOTEBORG, Sweden
Location
LITTLE ROCK, AR, United States
Location
HARTFORD, CT, United States
Location
PARK RIDGE, IL, United States
Location
LOUISVILLE, KY, United States
Arms | Assigned Interventions |
---|---|
Experimental: 1 Based on age and/or weight dose of esomeprazole IV qd in milligrams 20,40,10,20,10, 1.0 mg/kg, 0,5 mg/kg | Drug: esomeprazole IV qd for 4 days Other Name: Nexium |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.